|
Neoadjuvant gemcitabine/nab-paclitaxel-based chemoradiation therapy for borderline resectable pancreatic cancer.
|
|
Hidenori Takahashi1,
Daisaku Yamada1,
Osamu Ishikawa1 |
|
1Department of Gastroenterological Surgery, Osaka International Cancer Institute |
 |
|
| Purpose: The aim of this study is to investigate the treatment efficacy of neoadjuvant gemcitabine/nab-paclitaxel with concurrent radiation therapy (GnP-CRT) for borderline resectable pancreatic cancer (BRPC) in comparison with gemcitabine (GEM)-based CRT. Methods: A total of 244 patients with BRPC who received neoadjuvant GEM-CRT (Group G; n=151) or GnP-CRT (Group GnP; n=93) were retrospectively analyzed. The GEM-CRT protocol comprised the RT with concurrent GEM followed by the maintenance chemotherapy with GEM. The GnP-CRT protocol comprised the induction chemotherapy with GnP followed by the RT with concurrent GnP. Surgical outcomes were evaluated according to the neoadjuvant treatment protocols. Results: The cases with arterial involvements (BR-A) were more frequently observed in Group GnP (80%) than in Group G (62%) (p=0.007). The resection rates in Group G and GnP were 78% and 83% (p=0.38). The incidences of nodal involvements were similar in Group G and GnP (34% vs 34%). The major histological responses (Grade III/IV) were more frequently observed in Group GnP (29%) than in Group G (14%) (p=0.017). The 5-year survival rates of the entire cohort, including resected and unresected cases, were significantly higher in Group GnP (57%) than in Group G (32%) (p=0.024). Also, the 5-year survival rates of the resected cases were significantly higher in Group GnP (66%) than in Group G (40%) (p=0.042). Conclusion: Neoadjuvant GnP-based CRT would be a promising treatment strategy for BRPC. |
Index Term 1: pancreatic cancer
Index Term 2: neoadjuvant treatment
|
| Page Top |